Researchers discover how vaccine-induced immune thrombotic thrombocytopenia happens
A McMaster University team of researchers recently discovered how, exactly, the COVID-19 vaccines that use adenovirus vectors trigger a rare but sometimes fatal blood clotting reaction called vaccine-induced immune thrombotic thrombocytopenia or VITT.
The findings will put scientists on the path of finding a way to better diagnose and treat VITT, possibly prevent it and potentially make vaccines safer.
The researchers article was fast-tracked for publication today by the prestigious journal
Nature in its accelerated article preview because of the importance of the research.
Our work also answers important questions about the connection between antibodies and clotting.
A team of researchers at McMaster University in Hamilton found the cause of rare but sometimes fatal blood clots caused by certain vaccines.
The blood clotting reaction is known as vaccine-induced immune thrombotic thrombocytopenia (VITT). According to researchers, it’s much more severe than a typical blood clot because veins that drain blood from the brain are obstructed and can potentially cause fatal bleeding.
It’s believed that the findings will put scientists on the path of finding a way to better diagnose and treat VITT, possibly prevent it, and potentially make vaccines safer. Our work also answers important questions about the connection between antibodies and clotting, said Ishac Nazy, principal investigator and corresponding author of the study.
Study Uncovers How Some COVID-19 Vaccines Cause Blood Clots genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
McMaster researchers identify how VITT happens eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
A Canadian research team has published new evidence highlighting a combination of two treatments that could help patients suffering from a rare, but potentially-deadly, post-vaccine blood clot condition.